FDA expertise at issue as firms urge agency to take "big picture" view
This article was originally published in Clinica
Executive Summary
How the FDA handles its negotiations with companies prior to approving clinical trials was a common complaint at the third annual stakeholders meeting on the agency's medical device user fee programme, writes Karen Riley.